CD274 and neoplasm: Our PD-L1 data, currently limited to multiplex immunofluorescence analysis30 from patients in the pembrolizumab + paclitaxel arm of I-SPY2,7 shows a PD-L1 positivity (>1% PD-L1+ tumor cells) rate of 14% (4/28), and 2 of 4 of the PD-L1+ tumors were ImPrint+.